We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Evgen Pharma Plc | EVG | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.80 | 00:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.80 | 0.80 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 19/2/2024 11:25 by manual dexterity RNS Number : 6330DEvgen Pharma PLC 19 February 2024 Evgen Pharma plc ("Evgen" or "the Company" or "the Group") Positive update on SFX-01 in vitro Glioblastoma (GBM) studies Further evidence of SFX-01 activity as seen at other academic centres Alderley Park, UK - 19 February 2024: Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane-based medicines for the treatment of multiple diseases, announces that the laboratory of Dr Marjolein Geurts, neuro-oncologist at the Erasmus University Medical Centre has observed continuing activity of SFX-01 in GBM cells. The in vitro studies, which are supported by a grant awarded by the KWF Dutch Cancer Society for a €1.1m project, are designed to investigate the activity of SFX-01 in preclinical GBM models. This work is to be followed by administration of SFX-01 to patients with GBM in a clinical Investigator Sponsored Study (ISS). The scientific collaboration, which commenced in October 2023, will run for three years, generating data continuously throughout the period. According to the lead investigator, Dr Marjolein Geurts, neuro-oncologist at Erasmus University Medical Center, "We have seen continued evidence of biological activity in patient-derived glioblastoma tissue." Dr Huw Jones, CEO of Evgen Pharma said: "These early data triangulate with those seen by our other academic collaborators in Abbruzzo, Italy and Auckland, New Zealand. This is another major academic group observing these effects in tissue derived from a different population of GBM patients which gives us further confidence of SFX-01's potential as a therapeutic option for glioblastoma, a disease with very high unmet medical needs which is devastating for patients and their carers." -Ends- Enquiries Evgen Pharma plc Dr Huw Jones, CEO Toni Hänninen, CFO Dr Helen Kuhlman, CBO +44 207 457 2020 enquiries@evgen.com Cavendish Capital Markets (NOMAD and Broker) Geoff Nash / Teddy Whiley (Corporate Finance) Nigel Birks (ECM) +44 20 7220 0500 Instinctif Partners Melanie Toyne-Sewell / Jack Kincade +44 207 457 2020 Evgen@Instinctif.co |
Posted at 15/2/2024 09:38 by hatfullofsky 100% I am, EVG are part of my speculative high risk positions which are weighted appropriately. But I don't peddle fantasy, I'm simply in EVG for the potential upside and that will start to appear IF there is positive news from the studies. |
Posted at 15/2/2024 08:52 by hatfullofsky Clock - stop this fantasy, there is no way Stalicla will buy / RTO or any other form of acquisition of EVG. It's just not plausible, its fantasy thinking.The best we can hope for is that they pay their milestone payment and I think a Phase II study his now highly unlikely. That leaves EVG with 3 in vivo studies and one pre-clinical. Not an attractive position for any form of investment (apart from risk taking PI's of course) |
Posted at 13/2/2024 00:41 by w t tutte Clearly this situation is not a positive but I would make 3 points.1) This is within the context of an arbitration process and all that EVG have done so far is to say formally this is an issue that we are prepared to take further along the process. If you have ever been involved in any of these things you will know at almost every stage involved parties are sent back to talk more and very often things get resolved without lasting damage to the relationship. That may or may not happen here but at this point it is far from curtains. 2) A small outside possibility is that EVG has the someone else for the asset and wants it back. So is starting to escalate something small to put the pressure on Staliclia knowing they did not raise enough cash to progress SFX-01. 3) I find it rather odd, given they believe it is payable, that EVG would not have included the 500k in any cash forecasts for this year. |
Posted at 09/2/2024 11:56 by hatfullofsky So many disappointments with EVG but this is clearly on Stalicla.One plausible scenario is that Stalicla didn't have the funds for the payment end of last year, agreed with EVG to delay until a fundraise was completed. Fundraise now complete and Stalicla were still dragging their heels, so EVG forced their hand. This does not look good for Stalicla (or EVG) who would want to work with Stalicla if they renege on agreements. |
Posted at 09/2/2024 11:09 by tomboyb 09/02/2024 11:01amRNS Regulatory News RNS Number : 5388C Evgen Pharma PLC 09 February 2024 Evgen Pharma plc ("Evgen" or "the Company" or "the Group") Notice of Dispute lodged with Stalicla SA Alderley Park, UK - 9 February 2024: Evgen Pharma plc (AIM: EVG, Evgen), a clinical stage drug development company developing sulforaphane-based medicines, has issued a notice of dispute with Stalicla SA (Stalicla) its partner in autism spectrum disorder (ASD) and other neurodevelopmental disorders. In October 2022, Evgen licensed the global rights for lead asset SFX-01 in neurodevelopmental disorders and schizophrenia to Stalicla for up to $160.5m in milestone payments. An initial $0.5m was paid upfront with the next anticipated payment of $0.5m due on completion of the Evgen-sponsored human volunteer Phase 1 study. The Phase 1b human volunteer study was completed and the clinical study report finalised in August 2023. As announced on 16 January 2024, Evgen has been working with Stalicla on delivery of the associated milestone payment. The board of Evgen believes that the Company has met the terms required to satisfy the milestone, according to the License Agreement, and thus the payment is now due. In order to effect the payment, Evgen has taken the decision to formally implement the dispute resolution process detailed in the License Agreement, the first step of which is the issuance of a dispute notice. As stated in the half year results in October 2023, Evgen has not anticipated any milestone payments from Stalicla in its financial forecasting and its cash runway remains unchanged. Dr Huw Jones, Evgen CEO commented: "We continue to work closely with our partner for a quick and amicable resolution of the current dispute. We have taken a prudent approach of not recognising any milestone income in our cash projections and therefore the cash position remains unchanged. In the meantime we continue at pace with our internal programmes in oncology which are proceeding to plan." |
Posted at 21/1/2024 03:22 by w t tutte I do not understand the obsession with who is selling and why. It provides no new information. as anyone buying or selling has no better understanding of the situation than you or me.The only thing that matters here, at least as far an existing shareholders are concerned, is do Stalicla proceed to Phase II. EVG have a comfortable 12 months of cash which is sufficient time for this to play out or not. Stalicla proceed, cash runway is extended and value inflection point of going in to phase II gets baked in to valuation. Further cash is raised at much higher share price and time is bought for progress, in other indications, to play in to valuation. (Best Outcome) Stalicla do not proceed. EVG has limited cash remaining and no line of sight to any milestone payments. Share price crashes (yes, even from here) they raise a small amount to limp on but existing shareholders are wiped out. (Worst Outcome) The outlier that upsets this binary analysis is an unquantifiable event, which would skew positively and that would be that they conclude a deal in another indication that comes with a bit of cash. So how do you try to determine if Stalicla are likely to proceed or not ? Well this week in their Series B press release and now having most of the data they need to make an evaluation they have stated that they are continuing their work on STX01 Package. This would have been an easy point to drop the program, should they have wanted to. On the negative side it suggests, at this stage, they might not be looking to take it in to Phase II with their own cash. They may already have a partner lined up but at very least, it would suggest that they think the asset is capable of being partnered. The cost of taking this in to Phase II, including the milestone payment is likely to be @US$20 million. Which is more than they raised, but of course nothing to stop them coming back to raise for STX01, note in their press release that Stalicla refer to this raise as the FIRST round of the Series B. A couple of interesting things to note from linkedin, that may or may not be significant. 1) The New CFO seems to be based in Switzerland, as is Stalicla. Coincidence ? 2) I could not find a single EVG employee, including Huw, who liked the Stalicla Series B announcement. Suggests to me they do not see this event as directly impactful to EVG. So where do I sit, given the share price and the approach of Stalicla and also how hot the CNS sector is right now. I lean (60/40) towards STX01 moving in to phase II. I think this is most likely to happen via Staliclia entering in to a partnership (which I suspect is already lined up), however there is a sneaking suspicion that Staliclia is on a near term IPO track and may raise again in the near term with one of the use of proceeds to be taking STX01 in to Phase II. Will be looking to buy a few here but will be scaling and pricing it like a 12 month option (cash runway until they have to raise) and not an investment. |
Posted at 17/1/2024 12:12 by the imperialist “GDR, BLU, WSBN, and EVG.”GDR popped (first phase last week), BLU went today. EVG and WSBN left to complete the quartet for this month. ? EVG is clearly in-play. WSBN just started its journey with an 8% rise. NOTE: I've added NANO to the list. (not the same algorithm by which I can predict the aforementioned stock rises with precision, but a 20p stock considering a 10-11p special dividend. They are also cash-rich following a multi-million pound payout from Samsung). DYOR as always. |
Posted at 19/10/2023 13:35 by manual dexterity Evgen Pharma PLC19 October 2023 Evgen Pharma plc ("Evgen" or the "Company") Authored Article on Enteric Coating Formula Alderley Park, UK - 19 October 2023: Evgen Pharma plc (AIM: EVG), a clinical stage drug development company developing sulforaphane-based medicines for the treatment of cancer and other indications, highlights an article published today in respected industry publication The Medicine Maker, authored by Evgen's Chief Business Officer, Dr Helen Kuhlman. The article, entitled The Sulforaphane Promise, focuses on the recent study of Evgen's new enteric-coated tablet formulation, and why enteric coatings are of particular importance for a stabilised complex such as SFX-01 that releases highly biologically active sulforaphane. The SFX-01 complex is vulnerable to breakdown in acid conditions and the enteric coat prevents acid attack in the stomach, releasing the drug in the ideal region - the small bowel. It also discusses the pharmacodynamic and pharmacokinetic data from the recent study, demonstrating the improvements of the tablet formulation over previous formulations of SFX-01. The Medicine Maker is an online and print publication based in the United States, focusing on the entire spectrum of drug development and with a readership of pharmaceutical industry professionals across all levels. The article can be read online here. -Ends- |
Posted at 19/6/2023 06:08 by manual dexterity Evgen Pharma PLC Grant Success for Glioblastoma studies19/06/2023 7:00am UK Regulatory (RNS & others) Evgen Pharma (LSE:EVG) Intraday Stock Chart Monday 19 June 2023 Click Here for more Evgen Pharma Charts. TIDMEVG RNS Number : 0732D Evgen Pharma PLC 19 June 2023 Evgen Pharma plc ("Evgen" or "the Company" or "the Group") Evgen receives notification of grant success in the Netherlands for Glioblastoma Pre-clinical and Clinical Studies Grant provides non-dilutive funding for SFX-01 in glioblastoma 19 June 2023 - Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane-based medicines for the treatment of multiple diseases, announces that the Company's collaborator at The Erasmus University Medical Center, Rotterdam, NL has received a successful notice of a grant for Investigator Sponsored pre-clinical and clinical studies of SFX-01 in glioblastoma. The grant was awarded by KWF Dutch Cancer Society. The studies funded by the grant will cover use of SFX-01 in pre-clinical glioblastoma models, followed by a clinical Investigator Sponsored Study (ISS) window-of-opportunit Dr Huw Jones, CEO of Evgen Pharma said: "We announced earlier this year that our glioblastoma programme would be conducted as an ISS with non-dilutive funding. This award means that we remain on schedule to deliver this study in close collaboration with Dr Geurts. Congratulations to her and the Evgen team who compiled the grant application. The non-dilutive funding enables us to continue to preserve our capital and maintain our cash runway to the end of 2024 whilst continuing to generate valuable data on SFX-01. If the ISS and subsequent clinical trials succeed, SFX-01 will represent a novel and well tolerated option for patients with this devastating disease." Enquiries: Evgen Pharma plc Tel: +44 207 457 2020 Dr Huw Jones, CEO enquiries@evgen.com Richard Moulson, CFO FinnCap (Nominated Advisor and Tel: +44 20 7220 0500 Broker) Geoff Nash / Teddy Whiley (Corporate Finance) Alice Lane/Nigel Birks (ECM) Instinctif Partners Tel: +44 207 457 2020 Melanie Toyne-Sewell / Rozi Morris Evgen@Instinctif.com / Adam Loudon |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
